Andrew Gengos - 14 Feb 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Reporting relationship: CFO AND CHIEF BUSINESS OFFICER
Issuer ticker: ATHA
Reported as of: 14 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Feb 2024, 16:48:53 UTC
Prior SEC filing: 08 Jan 2024
Next SEC filing: 05 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Mark Worthington, Attorney-in-Fact for Andrew Gengos

Key filing fact

Andrew Gengos filed Form 4 for Athira Pharma, Inc. (ATHA) on 16 Feb 2024.

Key facts

This page summarizes Andrew Gengos's Form 4 filing for Athira Pharma, Inc. (ATHA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Feb 2024, 16:48.

Change

Previous filing in this sequence was filed on 08 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATHA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +280,000
Change %
Price: $0.000000
Shares after: 280,000
Date: 14 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 280,000
Exercise price: $3.26
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.